Welcure Drugs & Pharmaceuticals has signed a definitive mandate with Thailand-based Fortune Sagar Impex Company for third-party sourcing and procurement services.
The mandate, valued at ₹517 crore, is structured under an ex-works model and represents a significant milestone in Welcure’s service-led growth strategy.
As per the mandate, Welcure Drugs & Pharmaceuticals Ltd will engage in sourcing and procurement of multiple finished-dosage SKUs. Built on fee-based model, the company will earn fixed 5 per cent commission on the cost of goods. The estimated service income of ₹26 crore is expected in FY26, said the company.
The mandate enhances Welcure’s fee-based portfolio without incremental balance-sheet exposure, making this a high-margin growth opportunity, it added.
The buyer, Fortune Sagar Impex Company, Thailand, will be in-charge of responsibilities related to packaging, labelling, containerisation, insurance, freight and all destination-country regulatory clearances.